Urological Disorders

For patients with recurrent kidney stones, no difference seen in recurrence with hydrochlorothiazide 12.5, 25, 50 mg versus placebo

February 2023 Notable Drug Approvals

Findings of a phase 2 trial support the use of neoadjuvant chemotherapy as a standard of care, according to investigators.

Guidelines support the use of RAASi at the maximum tolerated dose in patients with CKD and heart failure.

Despite a warning from the FDA Adverse Event Reporting System, studies have found that SGLT2 inhibitor use is not associated with an increased risk of AKI.

Results from COVID-19 postexposure prophylaxis study of molnupiravir; Treatment approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy; Intravitreal injection approved for geographic atrophy secondary to AMD; Potential vaccines for melanoma and pregnant individuals to help protect against RSV complications in infants.

Sparsentan is an endothelin and angiotensin II receptor antagonist.

Device is safe and effective in real-world setting, providing high treatment success for vaginal and cesarean births

Improvement seen in median imaging-based progression-free survival, regardless of homologous recombination repair status

Postoperative opioid prescriptions are associated with delayed recovery, perioperative complications, and opioid misuse, investigators noted.

Up to 40% of patients with IgAN progress to end-stage kidney disease, investigators noted.

Increases seen in brain processing, penile tumescence, and behavioral measures of sexual desire and arousal

Significant negative impacts seen on activity, productivity, cost, and health-related quality of life

The FDA make revisions to EUAs for COVID-19 antivirals; Study finds possible new indication for beta blockers; Jesduvroq approved; Artificial tears product under investigation; Evusheld emergency use authorization halted.

Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.

The pembrolizumab combination was not associated with an improvement in overall survival or radiographic progression-free survival.

Patients with advanced CKD have not been well-represented in trials evaluating intensive blood pressure control.

Authors say the new algorithm could be used to safely withhold antibiotics in low-risk patients in the primary care setting

The two cases do not appear to have a direct connection to each other

The application is supported by data from the phase 3 EMPA-KIDNEY trial, which enrolled more than 6600 adults with CKD at risk of kidney disease progression.